newsfilter
← Latest News
GlobeNewswire·

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3